This is a working overview of GHS-R1a, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-09 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Moore and another Liverpool biochemist, Edward Whitney, founded the Biochemical Journal in 1906, one year after the creation of the US-based Journal of Biological Chemistry in 1905. Both journals still exist. Moore served as the first Biochemical Journal editor with the journal initially being published by the Liverpool University Press, the 3rd oldest University Press in England. Moore was concerned with the high mortality for the United Kingdom of pulmonary tuberculosis (TB), which he called the ‘Great White Plague', concluding that with 'the foundation of a new National Health Service and the provision of segregation for infectious cases in sanatoria, the disease could be eradicated'. Other holders of the Johnston Chair include RA Morton, FRS HH Rees, the late Trevour Goodwin FRS and the current Head of Department PA Eyers The Liverpool-originated Biochemical Journal was acquired by the London-based Biochemical Club (later renamed the Biochemical Society in 1911.
In a study on dinosterol side chain synthesis in the marine heterotrophic dinoflagellate, Crypthecodinium cohnii, the dinoflagellates were cultured with methionine-[CD3]. GC-MS analysis revealed that the C-23 methyl group contained three deuterium atoms that were introduced by transmethylation from methionine. The C-24 methyl group contained only two deuterium atoms, consistent with a 24-methylenesterol intermediate, which is reduced to the resulting 24-methyl side chain. This mechanism has been previously reported in fungi, a chrysophyte alga and a diatom. Importantly, no deuterium was incorporated into cholesterol or cholesta-5,7-dien-3β-ol, which are the major 4-methyl-sterols in Crypthecodinium cohnii. A suggested biosynthetic mechanism for side chain alkylations at C-23 and C-24 in dinosterol has been proposed.
Lately Chief Executive, Scottish Ambulance Service. For services to Emergency Health Care. Professor Ronald Edmund Hutton, FBA. Professor of History, University of Bristol. For services to History. Michelle Christina Jarman-Howe. Chief Operating Officer of Prisons, HM Prison and Probation Service. For Public Service. Michael Keith Jary. Lately Lead Non-Executive Director, Department for Levelling Up, Housing and Communities. For Public Service. Professor Alexandrina Henderson Farmer Jay, OBE. Lately Chair, Independent Inquiry into Child Sexual Abuse. For services to the Prevention of Child Sexual Abuse. Patricia Anne Jessopp. Chief Executive Officer, Royal Mint. For services to Industry and to the Financial Sector. Dr. Chandra Mohan Kanneganti. General Practitioner, Goldenhill Medical Centre, Stoke-on-Trent. For services to General Practice. Lynne Kelly. Chair and Trustee, Haemophilia Wales. For services to People with Haemophilia. Professor Timothy James Greaves Kendall. Lately National Clinical Director for Mental Health, NHS England. For services to Mental Health Care in England. Naguib Kheraj. Chair, Rothesay Limited. For services to Business and to the Economy. Christopher Ross Kingsley, OBE. Co-Founder and Chief Technology Officer, Rebellion. For services to the Creative Industries. Jonathon Jason Kingsley, OBE. Co-Founder, Chief Executive Officer and Creative Director, Rebellion. For services to the Creative Industries. David Eric Laing, DL. For services to Charity and to Philanthropy. Angela Marie Leitch. Lately Chief Executive, Public Health Scotland.
Sources: en.wikipedia.org
In July 2023, when Humira's regulatory exclusivity lapsed, a number of biosimilars such as Hadlima, Hyrimoz, Cyltezo, and Celltrion were launched in the US. In February 2024, adalimumab-ryvk (Simlandi) was approved for medical use in the United States.
As with regular coffee, the green coffee bean itself is first roasted to bring out flavour and aroma. Using rotating cylinders ovens, the green beans are heated to 165 °C (329 °F) for between 8 and 15 minutes. The beans are then cooled and ground into 0.5-to-1.1-millimetre (0.020 to 0.043 in) pieces. The main byproduct of the instant coffee production process is spent coffee grounds; they can be used as biomass, for example to produce heat used in the manufacturing process. The mass of spent coffee grounds is about twice that of the soluble coffee produced.
=== Relationship to land plants === Fossils of isolated spores suggest land plants may have been around as long as 475 million years ago (mya) during the Late Cambrian/Early Ordovician period, from sessile shallow freshwater charophyte algae much like Chara, which likely got stranded ashore when riverine/lacustrine water levels dropped during dry seasons. These charophyte algae probably already developed filamentous thalli and holdfasts that superficially resembled plant stems and roots, and probably had an isomorphic alternation of generations. They perhaps evolved some 850 mya and might even be as early as 1 Gya during the late phase of the Boring Billion.
== Motilin agonists == Erythromycin, Mitemcinal and related antibiotics act as non-peptide motilin agonists, and are sometimes used for their ability to stimulate gastrointestinal motility. In the case of erythromycin, it is its hemiketal intermediate, formed after an oral dose in the low-pH environment of the stomach lumen, which directly acts on the motilin receptor. Administration of a low dose of erythromycin will induce peristalsis, which provides additional support for the conclusion that motilin secretion triggers this pattern of gastrointestinal motility, rather than results from it. However, some of erythromycin's properties, including antibiotic activity, are not appropriate for a drug designed for chronic use over a patient's lifetime. New motilin agonists are erythromycin-based; however, it may be that this class of drugs becomes redundant. Growth hormone secretagogue receptors share 52% of their DNA with motilin receptors, and agonists of these receptors, termed ghrelins, can bring about similar effects to motilin agonists. Camicinal is a motilin agonist under development. Xylitol ingestion also increases motilin secretion, which may be related to xylitol's ability to cause diarrhea.
Sources: en.wikipedia.org
Vectorial synthesis is synthesis of exported proteins by ribosomes in which the ribosome-nascent chain complex is bound directly to the endoplasmic reticulum (ER) and the nascent peptide chain moves through the ER membrane as it emerges from the ribosome.
=== Pharmacodynamics === Prazosin is an α1-blocker that acts as a non-selective inverse agonist at α1-adrenergic receptors, including of the α1A-, α1B-, and α1D-adrenergic receptor subtypes. It binds to these receptors with affinity (Ki) values of 0.13 to 1.0 nM for the α1Α-adrenergic receptor, 0.06 to 0.62 nM for the α1B-adrenergic receptor, and 0.06 to 0.38 nM for the α1D-adrenergic receptor. It has much lower affinity for the α2-adrenergic receptors (Ki = 210–5,012 nM for the α2A-adrenergic receptor, 13–676 nM for the α2B-adrenergic receptor, and 10–257 nM for the α2C-adrenergic receptor). The α1-adrenergic receptors are found in vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. α1-Adrenergic receptors have additionally been found on immune cells, where catecholamine binding can stimulate and enhance cytokine production.
Pegulicianine, sold under the brand name Lumisight, is an optical imaging agent. It is given via intravenous injection. Pegulicianine was approved for medical use in the United States in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Dry powder is held at minus twenty degrees Celsius or colder, away from light and moisture. Sealed vials under inert gas limit degradation during storage.